凯因科技股价下跌1.98% 上半年净利润同比增长11.75%

Core Viewpoint - 凯因科技 is a high-tech biopharmaceutical company focused on viral and immune diseases, with a strong emphasis on innovative drug development and research [1] Financial Performance - For the first half of 2025, 凯因科技 reported revenue of 566 million yuan and a net profit attributable to shareholders of 47.38 million yuan, representing a year-on-year growth of 11.75% [1] - The company's R&D investment amounted to 71.41 million yuan, accounting for 12.61% of its revenue [1] Stock Performance - As of August 15, 2025, 凯因科技's stock price was 35.71 yuan, down 0.72 yuan or 1.98% from the previous trading day [1] - The stock opened at 36.40 yuan, reached a high of 36.42 yuan, and a low of 34.61 yuan, with a trading volume of 126,800 hands and a transaction value of 448 million yuan [1] Research and Development - The company has successfully developed proprietary drugs such as the all-oral pan-genotype hepatitis C drug and pegylated interferon α-2 injection [1] - Currently, 凯因科技 is focusing on the research and development of functional cure drug combinations for hepatitis B [1] - Several ongoing projects have made progress, including the phase III clinical trial for pegylated interferon α-2 injection for low-replication chronic HBV infection, which has been submitted for registration [1] Capital Flow - On the reporting day, the net outflow of main funds for 凯因科技 was 3.64 million yuan, accounting for 0.06% of its circulating market value [1] - Over the past five days, the net inflow of main funds was 27.79 million yuan, representing 0.46% of its circulating market value [1]